[{"id":"7a0a4fa0-562c-4834-ae83-73683d4790a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04852328","created_at":"2021-04-21T11:53:27.797Z","updated_at":"2025-02-25T16:38:23.751Z","phase":"Phase 2","brief_title":"Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma","source_id_and_acronym":"NCT04852328","lead_sponsor":"Washington University School of Medicine","biomarkers":" CDKN2A • CD8 • IFNG","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A • CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CUE-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-06"},{"id":"07d4b193-8962-44f1-ada5-2462a5073e52","acronym":"KEYNOTE-A78","url":"https://clinicaltrials.gov/study/NCT03978689","created_at":"2021-01-18T19:34:01.417Z","updated_at":"2025-02-25T16:09:12.255Z","phase":"Phase 1","brief_title":"A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03978689 - KEYNOTE-A78","lead_sponsor":"Cue Biopharma","biomarkers":" CDKN2A • CTLA4","pipe":" | ","alterations":" PD-L1 expression • CDKN2A expression","tags":["CDKN2A • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CDKN2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CUE-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-08-01"},{"id":"6efc2897-6d16-4902-9b72-1df2df9cb1ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04683393","created_at":"2021-01-19T20:47:06.839Z","updated_at":"2024-07-02T16:35:22.421Z","phase":"","brief_title":"A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.","source_id_and_acronym":"NCT04683393","lead_sponsor":"Manchester University NHS Foundation Trust","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2024-01-24"},{"id":"03c2d820-3476-4269-b264-4135249dcfe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01305954","created_at":"2021-01-18T05:18:44.777Z","updated_at":"2024-07-02T16:35:27.949Z","phase":"","brief_title":"Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients","source_id_and_acronym":"NCT01305954","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 04/03/2014","primary_completion_date":" 04/03/2014","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-28"},{"id":"23c9f80e-de2c-4354-8721-e76a55ae570e","acronym":"VICORYX-2","url":"https://clinicaltrials.gov/study/NCT02526316","created_at":"2021-01-18T12:12:53.368Z","updated_at":"2024-07-02T16:37:20.304Z","phase":"Phase 1","brief_title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers","source_id_and_acronym":"NCT02526316 - VICORYX-2","lead_sponsor":"Oryx GmbH \u0026 Co. KG","biomarkers":" CDKN2A • IFNG • CD4","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • VicOryx (P16_37-63)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2017-07-02"},{"id":"d5997ae4-23b6-4913-987e-be6fff8b06fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03100175","created_at":"2021-01-18T15:16:33.543Z","updated_at":"2024-07-02T16:37:23.805Z","phase":"","brief_title":"Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Aging","source_id_and_acronym":"NCT03100175","lead_sponsor":"Rabin Medical Center","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A expression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A expression"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 03/15/2019","primary_completion_date":" 03/15/2019","study_txt":" Completion: 03/15/2019","study_completion_date":" 03/15/2019","last_update_posted":"2017-04-04"}]